The Hong Kong Polytechnic University (PolyU) has achieved further breakthrough in developing cancer drugs through making use of advanced biotechnology. This breakthrough not only gives a ray of hope for cancer patients, but also revolutionizes the concept of cancer drug development.
This innovation has recently been awarded the Prize of the State of Geneva (third runner-up prize) and a Gold Medal with Jury’s Commendation at the 37th International Exhibition of Inventions, New Techniques and Products of Geneva.
Developed by Associate Professor Dr Thomas Leung Yun-chung and Assistant Professor Dr Thomas Lo Wai-hung of the University's Department of Applied Biology and Chemical Technology, the new drugs work on the mechanism of starving cancer cells through depletion of arginine - a key nutrient for many cancer cells.
PolyU researchers have proved that the depletion or lowering of blood arginine concentrations is effective in inhibiting the proliferation of liver cancer. The research paper on this important finding was first published in the authoritative, highly cited journal Cancer Research, published by the American Association for Cancer Research (January 2007 issue). This paper has shed new light on the development of novel arginine-depleting cancer drug for treating liver cancer (hepatocellular carcinoma).
The main constituent of this new drug is arginase, an enzyme that degrades arginine, with urea as an end-product. However, naturally occurring arginase has a very short half-life and thus cannot be used for therapeutic purpose. Using state-of-the-art DNA technology, PolyU researchers produced in 2005 a recombinant human arginase that, after chemical modification, has a significantly prolonged half-life for therapeutic use. More recently, they have further invented a novel drug based on naturally occurring thermostable Bacillus arginase (BCA). A patent application has been filed for this novel drug.
This breakthrough has a far-reaching impact in that the second generation of cancer drugs developed by PolyU researchers could provide a cure not just for liver cancer, but also for other deadly cancer diseases. In the laboratory settings, the new drug has been proved to work in cell culture for breast cancer, cervical cancer, skin cancer, pancreatic cancer, lung cancer, colorectal cancer, and gastric cancer.
Pre-clinical studies conducted on the use of this drug in nude mice showed that the drug is effective in depleting blood arginine and inhibiting breast cancer. The use of this new drug has opened up many new opportunities for effective treatment of different types of cancer. As this anti-cancer therapy is a targeted approach, it only affects cancer cells but not normal cells, causing less side effects than traditional cytotoxic chemotherapy.
Furthermore, the new drug is more stable with a longer blood circulating half-life, which means cancer patients can receive fewer injections of smaller amounts of this drug to achieve the same result. The new drug is also purer because of its homogenous structure and the production cost is expected to be lower because of its simple form.
The first generation of cancer drug based on arginine depletion has been proved to work on liver cancer and is now going through the clinical trial stages with the support of Queen Mary Hospital and the Centre for the Study of Liver Diseases at the University of Hong Kong. The second generation of cancer drugs will also go through similar testing stages in the years ahead.
The discovery of this new drug is supported by research funding from the Lo Ka Chung Charity Foundation and the Simatelex Charitable Foundation. The research work is being undertaken at the University’s Lo Ka Chung Centre for Natural Anti-Cancer Drug Development, which was set up in December 2006 with a generous donation of HK$20 million from Mr Lo.
This innovation, together with the descriptions of five other intriguing research projects, are being put on public display at the "PolyU Achievements Exhibition" which runs from 6 to 9 April on the university campus.
Evelyn Chan | Research asia research news
Further reports about: > Bacillus arginase > Cancer > Exhibition > PolyU > Polytechnic > advanced biotechnology > arginase > arginine > breast cancer > cancer cells > cancer drugs > cancer patients > cervical cancer > chemical modification > colorectal cancer > gastric cancer > liver cancer > lung cancer > nude mice > skin cancer > traditional cytotoxic chemotherapy
First time-lapse footage of cell activity during limb regeneration
25.10.2016 | eLife
Phenotype at the push of a button
25.10.2016 | Institut für Pflanzenbiochemie
Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.
This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
25.10.2016 | Earth Sciences
25.10.2016 | Power and Electrical Engineering
25.10.2016 | Process Engineering